Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
This is a phase I study evaluating the safety and pharmacokinetics of MBS301 after intravenous administration in patients with HER-2 positive recurrent or metastatic malignant solid tumors
HER2-positive Recurrent or Metastatic Malignant Solid Tumor
DRUG: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
DLT of MBS301, Evaluate the safety of MBS301 and determine the dose limited toxicity (DLT) ., up to the third treatment cycle of the last subject was ended (each cycle is 21 days)|MTD of MBS301, Evaluate the safety of MBS301 and determine the maximum tolerated dose (MTD)., up to the third treatment cycle of the last subject was ended (each cycle is 21 days)
Investigate the pharmacokinetics profile(Cmax) of MBS301, Maximum Plasma Concentration \[Cmax\], At the end of Cycle 3 (each cycle is 21 days)|Investigate the pharmacokinetics profile(AUC) of MBS301, Area Under the Curve \[AUC\], At the end of Cycle 3 (each cycle is 21 days)|Investigate the pharmacokinetics profile(Tmax) of MBS301, Time for Peak concentration\[Tmax\], At the end of Cycle 3 (each cycle is 21 days)|Investigate the pharmacokinetics profile(MRT) of MBS301, Mean ResidenceTime\[MRT\], At the end of Cycle 3 (each cycle is 21 days)|Investigate the pharmacokinetics profile(T1/2) of MBS301, Half-life\[T1/2\], At the end of Cycle 3 (each cycle is 21 days)|Investigate the pharmacokinetics profile(Vd) of MBS301, Apparent volume of distribution\[Vd\], At the end of Cycle 3 (each cycle is 21 days)|Investigate the pharmacokinetics profile(CL) of MBS301, Clearance\[CL\], At the end of Cycle 3 (each cycle is 21 days)|Evaluate the immunogenicity of MBS301, Anti-drug antibody (ADA), screening, before the second/third cycle of administration, Cycle 1 day 15, at the end of Cycle 3 (each cycle is 21 days)|Evaluate the objective response rate (ORR)of MBS301, objective response rate (ORR), up to approximately 2 years|Evaluate the duration of response (DoR) of MBS301, duration of response (DoR), up to approximately 2 years|Evaluate the disease control rate (DCR) of MBS301, disease control rate (DCR), up to approximately 2 years|Evaluate the progression free survival (PFS) of MBS301, progression free survival (PFS), up to approximately 2 years
This is a phase I study evaluating the safety and pharmacokinetics of MBS301 after intravenous administration in patients with HER-2 positive recurrent or metastatic malignant solid tumors